Search
Research
Brain TumourBrain tumours are the second most common cancer in children (after leukaemia).
Research
Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolismWe examined the baseline profile of a panel of T-ALL cell lines to determine factors that contribute to GC resistance without prior drug selection.
Research
Prenatal origins and health outcomes of male reproductive congenital anomalies diagnosed at birth and testicular cancer in adulthoodThis study involves record linkage of birth, birth defects, hospital, deaths and cancer data; with links to genealogy data to identify links between families.
Research
Australian Study of Causes of Acute Lymphoblastic Leukaemia in ChildrenAnalysing data collected between 2003 and 2007 in this national case-control study of the risk factors for childhood acute lymphoblastic leukaemia (ALL).
People
Timo LassmannFeilman Fellow; Program Head, Precision Health and Team Lead, Computational Biology
News & Events
The Kids Research Institute Australia researchers share in State Government science grantsFour The Kids Research Institute Australia researchers are among those who have received funding in the WA State Government's Merit Award Program announced today.
News & Events
New drug hope for babies with leukaemiaResearchers at The Kids Research Institute Australia have discovered a new drug combination that could help improve survival rates for babies with leukaemia.
News & Events
A cell change that drives leukaemiaIt is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.
News & Events
WA families to help find triggers for childhood leukaemiaWest Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.
Research
Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockadeAntibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4, programmed cell death protein/ligand 1 are approved for treatment of multiple cancer types.